Navigation Links
TGen and Virginia G. Piper Cancer Center form drug development collaboration with Cedars-Sinai
Date:11/8/2011

SCOTTSDALE, Ariz. -- The Virginia G. Piper Cancer Center at Scottsdale Healthcare is expanding its efforts to accelerate advances in cancer care with the addition of Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute in Los Angeles as a collaborator in clinical trials to develop personalized therapies that could lead to more effective cancer treatments.

The collaboration will focus on Phase I clinical trials of new personalized therapies for a variety of rare and common cancers, focusing on three areas of cancer research:

  • Gastrointestinal malignancies including pancreatic, colorectal and gastric cancer
  • Genitourinary malignancies such as prostate, kidney and bladder cancer
  • Rare cancers including adrenal, neuroendocrine and thyroid cancer

Virginia G. Piper Cancer Center Clinical Trials, a partnership between the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, will provide local coordination for the program. The partnership offers patients access to promising new cancer treatments through clinical trials, emphasizing collaboration among leading organizations to speed innovation from laboratory bench to patient bedside.

The collaborative endeavor between TGen, Virginia G. Piper Cancer Center and Cedars-Sinai also will study new approaches to improve patients' quality of life during cancer treatment and create innovative models to deliver supportive care and services to cancer survivors.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare serves the greater Phoenix area with innovative cancer treatment and research facilities that attract patients from across Arizona and the United States.

"In addition to our local patients a significant number travel from the west coast for treatment at the Virginia G. Piper Cancer Center. The opportunity to expand our collective efforts against these cancers will undoubtedly mean progress in medicine's ability to successfully treat the disease," said Dr. Ramesh Ramanathan, M.D., Medical Director, Virginia G. Piper Cancer Center Clinical Trials, and Deputy Director of TGen's Clinical Translational Research Division.

Cedars-Sinai is the largest academic medical center in the western U.S. Its outpatient cancer center treats more than 9,000 patients each year, making it one of the busiest treatment facilities in California. Earlier this year, U.S. News & World Report named the institute's cancer program as one of the top in the country.

"Our two organizations share the same goal: to greatly improve cancer treatment with therapies that attack the disease in new and innovative ways," added Steven Piantadosi, M.D., Ph.D., Phase One Foundation chair and director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. "Translating new research into effective therapies will improve the lives of cancer patients, and, ultimately, lead to a time when cancer is a manageable condition not a feared disease."

The Virginia G. Piper Cancer Center at Scottsdale Healthcare opened in December 2001 as the first comprehensive cancer center in greater Phoenix and ranks as one of the country's leading programs for new cancer drug development and Phase I studies.

"We are very excited about this new collaboration intended to accelerate development of new ways to beat cancer," said Tom Sadvary, president & CEO of Scottsdale Healthcare. "Our two organizations share the same commitment to improving the lives of our patients and expanding the ever-increasing number of cancer survivors."

Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339; toll free at 1-877-273-3713; or via email at clinicaltrials@shc.org.


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Virginia Commonwealth University findings may help explain high blood pressure in pregnancy
2. Virginia Commonwealth University study: We are what we experience
3. TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
4. TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
5. Months After Shootings, Many Virginia Tech Students Suffered PTSD
6. TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
7. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
8. Virginia Bioinformatics Institute to model immune responses to gut pathogens
9. Virginia Tech professor discovers new TB pathogen
10. VCU first Virginia institution to join national network of academic research centers
11. Dr. Phillip Chang Introduces New Ways to Decrease Scars and Potential Complications For Breast Augmentations in Loudoun and Fairfax Virginia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology: